CEO Patrick Miles was paid $10,260,507 in fiscal year 2025, ↑ up 64.9% from fiscal year 2024, the 65th percentile of its disclosed peer group (SEC filing 0001193125-26-191867 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,260,507 ↑ Patrick Miles total, FY2025 | 65th CEO pay percentile vs peers | 77.8:1 CEO-to-median pay ratio | 86.84% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
Ask our research desk — $99, 24h, every figure cited to its filing.
ATEC's next annual pay disclosure, estimated May 3, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Patrick Miles | $762,000 | $0 | $8,859,650 | $0 | $600,000 | $0 | $38,857 | $10,260,507 |
| President, Chairman and Chief Executive Officer | ||||||||
| Craig Hunsaker | 498,625 | 0 | 4,515,970 | 0 | 257,500 | 0 | 1,047,777 | 6,319,872 |
| Executive Vice President, People & Culture | ||||||||
| Scott Lish | 485,009 | 0 | 4,494,154 | 0 | 257,500 | 0 | 34,582 | 5,271,245 |
| Chief Operating Officer | ||||||||
| David Sponsel | 445,390 | 0 | 3,024,662 | 0 | 450,000 | 0 | 34,355 | 3,954,407 |
| Executive Vice President, Sales | ||||||||
| J. Todd Koning | 480,775 | 0 | 3,062,444 | 0 | 250,000 | 0 | 36,656 | 3,829,875 |
| Executive Vice President and Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Patrick Miles | $10,260,507 | $6,221,699 | $9,477,979 | ↑ +4,038,808 |
| Craig Hunsaker | 6,319,872 | 3,417,233 | 4,569,021 | ↑ +2,902,639 |
| Scott Lish | 5,271,245 | 2,575,871 | 2,585,149 | ↑ +2,695,374 |
| David Sponsel | 3,954,407 | 2,803,029 | 3,214,860 | ↑ +1,151,378 |
| J. Todd Koning | 3,829,875 | 2,616,961 | 3,360,339 | ↑ +1,212,914 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Alphatec Holdings's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper ATEC reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
How we handle your data → Privacy
Each company listed discloses ATEC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATEC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
One page per officer: the same table above, read for one person at a time — his own figure and every fiscal year the register holds.
| Executive | Role | FY2025 total |
|---|---|---|
| Craig Hunsaker | EVP | $6,319,872 |
| J. Todd Koning | CFO | $3,829,875 |
| Patrick Miles | CEO | $10,260,507 |
| Scott Lish | COO | $5,271,245 |
| David Sponsel | EVP | $3,954,407 |
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| David Demski | Independent Director | $222,487 |
| David Pelizzon | Independent Director | $222,487 |
| Karen McGinnis | Independent Director | $249,987 |
| Keith Valentine | Independent Director | $227,487 |
| Mortimer Berkowitz | Independent Director | $242,487 |
| Quentin Blackford | Independent Director | $239,987 |
| Ward Woods | Independent Director | $237,487 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Keith Valentine | Director | 2026-05-07 | A | 56,153 | $7 | $420,586 | Common | Form 4 ↗ |
| Keith Valentine | Director | 2026-05-08 | A | 43,847 | 8 | 330,606 | Common | Form 4 ↗ |
| Keith Valentine | Director | 2026-05-11 | A | 35,000 | 7 | 245,000 | Common | Form 4 ↗ |
| Mortimer Berkowitz | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| David Demski | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| David Pelizzon | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| Keith Valentine | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| Quentin Blackford | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| Karen McGinnis | Director | 2026-06-10 | A | 32,012 | 0 | 0 | Common | Form 4 ↗ |
| Karen McGinnis | Director | 2026-06-11 | D | 6,050 | 8 | 48,461 | Common | Form 4 ↗ |
| Tyson Eliot Marshall | GENERAL COUNSEL & CORP. SEC. | 2026-08-05 | D | 8,168 | 10 | 78,821 | Common | Form 4 ↗ |
| Patrick Miles | Director | 2026-09-10 | A | 115,000 | 9 | 1,013,150 | Common | Form 4 ↗ |
| Thomas Andrew Carls | EVP, Data & Imaging Solutions | 2026-10-05 | A | 200,000 | 0 | 0 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Sponsel | RSU | 2025-06-11 | — | — | 3,866 | — | $45,348 |
| J. Todd Koning | RSU | 2025-01-29 | — | — | 133,920 | — | 1,615,075 |
| J. Todd Koning | RSU | 2025-06-11 | — | — | 20,929 | — | 245,497 |
| Scott Lish | RSU | 2025-06-11 | — | — | 21,751 | — | 255,139 |
| Patrick Miles | RSU | 2025-01-29 | — | — | 389,195 | — | 4,693,692 |
| Craig Hunsaker | RSU | 2025-06-11 | — | — | 21,751 | — | 255,139 |
| Patrick Miles | RSU | 2025-06-11 | — | — | 16,475 | — | 193,252 |
| Craig Hunsaker | RSU | 2025-01-29 | — | — | 195,126 | — | 2,353,220 |
| Scott Lish | PSU | 2025-01-29 | — | 173,417 | — | 346,834 | 2,091,409 |
| David Sponsel | PSU | 2025-01-29 | — | 114,322 | — | 228,644 | 1,378,723 |
| J. Todd Koning | PSU | 2025-01-29 | — | 114,322 | — | 228,644 | 1,378,723 |
| Scott Lish | RSU | 2025-01-29 | — | — | 193,317 | — | 2,331,403 |
| Patrick Miles | PSU | 2025-01-29 | — | 340,955 | — | 681,910 | 4,111,917 |
| David Sponsel | RSU | 2025-01-29 | — | — | 135,428 | — | 1,633,262 |
| Craig Hunsaker | PSU | 2025-01-29 | — | 173,417 | — | 346,834 | 2,091,409 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Sponsel | $1,678,610 | $1,378,723 | $0 | 45.1% |
| J. Todd Koning | 1,860,572 | 1,378,723 | 0 | 42.6% |
| Scott Lish | 2,586,542 | 2,091,409 | 0 | 44.7% |
| Patrick Miles | 4,886,944 | 4,111,917 | 0 | 45.7% |
| Craig Hunsaker | 2,608,359 | 2,091,409 | 0 | 44.5% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Scott Lish | PSU | 80,635 | — | $1,696,553 |
| J. Todd Koning | PSU | 43,204 | — | 909,012 |
| Patrick Miles | PSU | 207,755 | — | 4,371,163 |
| Patrick Miles | RSU | 340,955 | — | 7,173,693 |
| Patrick Miles | PSU | 340,955 | — | 7,173,693 |
| Scott Lish | PSU | 173,417 | — | 3,648,694 |
| Patrick Miles | PSU | 137,854 | — | 2,900,448 |
| Patrick Miles | PSU | 103,391 | — | 2,175,347 |
| David Sponsel | PSU | 114,322 | — | 2,405,335 |
| Scott Lish | RSU | 173,417 | — | 3,648,694 |
| Craig Hunsaker | RSU | 173,417 | — | 3,648,694 |
| Craig Hunsaker | PSU | 173,417 | — | 3,648,694 |
| J. Todd Koning | RSU | 114,322 | — | 2,405,335 |
| David Sponsel | RSU | 23,375 | — | 491,810 |
| J. Todd Koning | PSU | 114,322 | — | 2,405,335 |
| Craig Hunsaker | PSU | 46,175 | — | 971,522 |
| David Sponsel | RSU | 114,322 | — | 2,405,335 |
| J. Todd Koning | PSU | 80,635 | — | 1,696,553 |
| Craig Hunsaker | PSU | 104,622 | — | 2,201,257 |
| David Sponsel | PSU | 89,060 | — | 1,873,819 |
| J. Todd Koning | PSU | 32,403 | — | 681,759 |
| Patrick Miles | RSU | 68,238 | — | 1,435,728 |
| Craig Hunsaker | PSU | 61,566 | — | 1,295,349 |
| Patrick Miles | RSU | 54,529 | — | 1,147,290 |
| David Sponsel | PSU | 30,314 | — | 637,807 |
| David Sponsel | PSU | 40,418 | — | 850,395 |
| J. Todd Koning | RSU | 21,385 | — | 449,940 |
| Scott Lish | PSU | 33,388 | — | 702,484 |
| Scott Lish | PSU | 25,041 | — | 526,863 |
| Craig Hunsaker | RSU | 30,475 | — | 641,194 |
| Craig Hunsaker | RSU | 27,460 | — | 577,758 |
| David Sponsel | RSU | 20,007 | — | 420,947 |
| J. Todd Koning | RSU | 21,164 | — | 445,291 |
| Scott Lish | RSU | 21,164 | — | 445,291 |
| Scott Lish | RSU | 16,527 | — | 347,728 |
The Compensation Committee designs executive compensation to attract, motivate, and retain highly qualified executives, aligning their interests with those of stockholders through a mix of cash and equity-based incentives.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-10 | 81,927,395 | 12,420,476 | 293,219 | 86.84% | Passed |
| 2025 | 2025-06-11 | 82,619,803 | 6,064,612 | 65,969 | 93.16% | Passed |
| 2024 | 2024-06-12 | 69,776,291 | 12,628,164 | 49,825 | 84.68% | Passed |
| 2023 | 2023-06-14 | 56,507,999 | 728,685 | 30,493 | 98.73% | Passed |
| 2022 | 2022-06-15 | 37,605,393 | 18,739,526 | 356,643 | 66.74% | Passed |
| 2021 | 2021-06-16 | 55,107,427 | 3,693,015 | 591,634 | 93.72% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-10 | 86.84%a |
| 2025 | 2025-06-11 | 93.16%b |
| 2024 | 2024-06-12 | 84.68%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 77.8 : 1 |
|---|---|
| CEO total compensation | $10,260,507 |
| Median employee compensation | $131,967 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Karen McGinnisIndependent · Audit Committee (Chair) · Compensation Committee (Chair) | $72,500 | $177,487 | — | — | — | $249,987 |
| Mortimer BerkowitzIndependent · Audit Committee · Nominating and Corporate Governance Committee (Chair) · Compensation Committee | 65,000 | 177,487 | — | — | — | 242,487 |
| Quentin BlackfordIndependent · Audit Committee · Compensation Committee | 62,500 | 177,487 | — | — | — | 239,987 |
| Ward WoodsIndependent · Compensation | 60,000 | 177,487 | — | — | — | 237,487 |
| Keith ValentineIndependent · Nominating and Corporate Governance Committee | 50,000 | 177,487 | — | — | — | 227,487 |
| David DemskiIndependent · Audit · Compensation | 45,000 | 177,487 | — | — | — | 222,487 |
| David PelizzonIndependent | 45,000 | 177,487 | — | — | — | 222,487 |
| Patrick MilesEmployee director · Audit · Nominating and Corporate Governance · Compensation | — | — | — | — | — | 0 |
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | $135,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $400,000 |
| Equity awards (grant-date value) | $1,242,409 |
| All other compensation | $0 |
| Total cost of the board | $1,642,409 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Alphatec Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Alphatec Holdings.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Doximity | 2026 | Jeff Tangney | $627,000 | $18,955,899 | $0 | $0 | $19,586,169 |
| 2 | NovoCure | 2025 | Ashley Cordova | 901,837 | 8,249,965 | 2,752,814 | 811,653 | 13,198,354 |
| 3 | Glaukos | 2025 | Thomas Burns | 850,000 | 7,649,947 | 3,527,497 | 0 | 12,034,087 |
| 4 | Nevro | 2023 | Kevin Thornal | 515,625 | 10,080,173 | 0 | 402,750 | 11,453,548 |
| 5 | iRhythm Technologies | 2025 | Quentin Blackford | 700,003 | 8,919,457 | 0 | 1,350,000 | 11,003,163 |
| 6 | TransMedics Group | 2025 | Waleed Hassanein | 776,923 | 4,364,013 | 4,360,147 | 1,400,000 | 10,915,533 |
| 7 | Alphatec Holdings | 2025 | Patrick Miles | 762,000 | 8,859,650 | 0 | 600,000 | 10,260,507 |
| 8 | Maravai Life Sciences Holdings | 2025 | Bernd Brust | 388,863 | 7,660,000 | 1,460,000 | 425,343 | 10,129,708 |
| 9 | AtriCure | 2025 | Michael Carrel | 828,439 | 7,203,478 | 0 | 1,171,703 | 9,217,620 |
| 10 | LivaNova | 2025 | Vladimir Makatsaria | 956,115 | 4,303,092 | 1,374,999 | 1,287,656 | 8,047,217 |
| 11 | Inspire Medical Systems | 2025 | Timothy Herbert | 750,572 | 5,999,655 | 0 | 961,557 | 7,711,784 |
| 12 | Artivion | 2025 | J. Patrick Mackin | 835,145 | 5,006,990 | 0 | 991,368 | 6,883,108 |
| 13 | Tandem Diabetes Care | 2025 | John Sheridan | 790,583 | 5,367,796 | 0 | 674,090 | 6,858,503 |
| 14 | 10x Genomics | 2025 | Serge Saxonov | 674,250 | 5,020,269 | 0 | 634,725 | 6,329,244 |
| 15 | STAAR Surgical | 2025 | Adam Wyll | 750,000 | 2,228,916 | 0 | 952,500 | 4,806,038 |
| 16 | LeMaitre Vascular | 2025 | George LeMaitre | 806,347 | 1,050,000 | 1,050,000 | 680,015 | 3,780,990 |
| 17 | Paragon 28 | 2025 | Douglas Kennedy | 936,000 | 863,540 | 0 | 1,205,341 | 3,479,531 |
| 18 | Zynex | 2024 | Thomas Sandgaard | 700,000 | 112,458 | — | 170,625 | 991,810 |
| — | Tactile Systems Technology | — | — | — | — | — | — | not in coverage universe |
| — | Treace Medical Concepts | — | — | — | — | — | — | not in coverage universe |
| — | OraSure Technologies | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Alphatec Holdings | 157% | PSU 50 · RSU 50 | No | Compensia |
| 10x Genomics | 93% | PSU 60 · RSU 40 | Yes — 3-year Relative TSR | Alpine Rewards LLC |
| Artivion | 118.7% | PSU 50 · RSU 50 | No | Willis Towers Watson |
| AtriCure | 141% | PSU 70 · RSU 30 | No | Korn Ferry |
| Doximity | not disclosed | not disclosed | No | Aon plc (Human Capital Solutions Practice) |
| Glaukos | 177.5% | RSU 50 · PRSU 50 | No | Frederic W. Cook & Co., Inc. |
| Inspire Medical Systems | 111.4% | PSU 50 · RSU 50 | No | Aon |
| iRhythm Technologies | 173% | RSU 50 · PSU 50 | Yes — Relative TSR | Aon and Mercer |
| LeMaitre Vascular | not disclosed | Option 50 · RSU 25 · PSU 25 | No | not disclosed |
| LivaNova | 122.4% | PSU 50 · RSU 25 · Options 25 | No | Pearl Meyer |
| Maravai Life Sciences Holdings | not disclosed | not disclosed | No | Meridian Compensation Partners, LLC |
| Nevro | 53.7% | not disclosed | No | Aon |
| NovoCure | 100% | PSU 50 · RSU 25 · Options 25 | No | Frederic W. Cook & Co., Inc. |
| OraSure Technologies | not disclosed | not disclosed | not disclosed | not disclosed |
| Paragon 28 | 120% | RSU 100 | Yes — TSR | Aon |
| STAAR Surgical | 191% | PSU 100 | Yes — Relative Total Shareholder Return (TSR) vs. S&P 600 Real Estate Index | not disclosed |
| Tactile Systems Technology | not disclosed | not disclosed | not disclosed | not disclosed |
| Tandem Diabetes Care | 87% | PSU 50 · RSU 50 | Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027 | WTW |
| TransMedics Group | 175% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Treace Medical Concepts | not disclosed | not disclosed | not disclosed | not disclosed |
| Zynex | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Patrick Miles | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “2025 Summary Compensation Table”. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 2 | Section 01, Craig Hunsaker | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “2025 Summary Compensation Table”. As printed: 6,319,872. Filing ↗machine: t26 · r8 · c25 · span 920209–920218 |
| 3 | Section 01, Scott Lish | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “2025 Summary Compensation Table”. As printed: 5,271,245. Filing ↗machine: t26 · r14 · c25 · span 982119–982128 |
| 4 | Section 01, David Sponsel | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “2025 Summary Compensation Table”. As printed: 3,954,407. Filing ↗machine: t26 · r11 · c25 · span 951186–951195 |
| 5 | Section 01, J. Todd Koning | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “2025 Summary Compensation Table”. As printed: 3,829,875. Filing ↗machine: t26 · r5 · c25 · span 889176–889185 |
| 6 | Section 03, David Sponsel RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r25 · c9 · span 1149611–1149617 |
| 7 | Section 03, J. Todd Koning RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r12 · c9 · span 1099454–1099463 |
| 8 | Section 03, J. Todd Koning RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r13 · c9 · span 1103362–1103369 |
| 9 | Section 03, Scott Lish RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r31 · c9 · span 1172728–1172735 |
| 10 | Section 03, Patrick Miles RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r6 · c9 · span 1076328–1076337 |
| 11 | Section 03, Craig Hunsaker RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r19 · c9 · span 1126486–1126493 |
| 12 | Section 03, Patrick Miles RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r7 · c9 · span 1080236–1080243 |
| 13 | Section 03, Craig Hunsaker RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r18 · c9 · span 1122578–1122587 |
| 14 | Section 03, Scott Lish PSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r29 · c9 · span 1164911–1164920 |
| 15 | Section 03, David Sponsel PSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r23 · c9 · span 1141795–1141804 |
| 16 | Section 03, J. Todd Koning PSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r11 · c9 · span 1095545–1095554 |
| 17 | Section 03, Scott Lish RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r30 · c9 · span 1168820–1168829 |
| 18 | Section 03, Patrick Miles PSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r5 · c9 · span 1072419–1072428 |
| 19 | Section 03, David Sponsel RSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r24 · c9 · span 1145704–1145713 |
| 20 | Section 03, Craig Hunsaker PSU | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t27 · r17 · c9 · span 1118669–1118678 |
| 21 | Section 07, pay ratio | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “CEO Pay Ratio”. As printed: 77.8 : 1. Filing ↗machine: span 833563–833570 |
| 22 | Section 08, Karen McGinnis | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 249,987. Filing ↗machine: span 1747775–1748015 |
| 23 | Section 08, Mortimer Berkowitz | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 242,487. Filing ↗machine: span 1732777–1733017 |
| 24 | Section 08, Quentin Blackford | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 239,987. Filing ↗machine: span 1737779–1738019 |
| 25 | Section 08, Ward Woods | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 237,487. Filing ↗machine: span 1763045–1763285 |
| 26 | Section 08, Keith Valentine | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 227,487. Filing ↗machine: span 1757774–1758014 |
| 27 | Section 08, David Demski | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 222,487. Filing ↗machine: span 1742776–1743016 |
| 28 | Section 08, David Pelizzon | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 222,487. Filing ↗machine: span 1752774–1753014 |
| 29 | Section 08, Patrick Miles | DEF 14A | 2026-04-29 | 0001193125-26-191867 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 30 | Section 02, Keith Valentine 2026-05-07 | Form 4 | 2026-05-11 | 0001289408-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Keith Valentine 2026-05-08 | Form 4 | 2026-05-11 | 0001289408-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Keith Valentine 2026-05-11 | Form 4 | 2026-05-11 | 0001289408-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Mortimer Berkowitz 2026-06-10 | Form 4 | 2026-06-12 | 0001364333-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, David Demski 2026-06-10 | Form 4 | 2026-06-12 | 0001555392-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, David Pelizzon 2026-06-10 | Form 4 | 2026-06-12 | 0001719217-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Keith Valentine 2026-06-10 | Form 4 | 2026-06-12 | 0001289408-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Quentin Blackford 2026-06-10 | Form 4 | 2026-06-12 | 0001612451-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Karen McGinnis 2026-06-10 | Form 4 | 2026-06-12 | 0001188264-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Karen McGinnis 2026-06-11 | Form 4 | 2026-06-12 | 0001188264-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Tyson Eliot Marshall 2026-08-05 | Form 4 | 2026-08-07 | 0001666669-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Patrick Miles 2026-09-10 | Form 4 | 2026-09-10 | 0001289409-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Thomas Andrew Carls 2026-10-05 | Form 4 | 2026-10-05 | 0002155784-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 06, 2026 vote | Form 8-K | 2026-06-11 | 0001193125-26-267552 | Item 5.07 · say-on-pay result. As reported: 86.84% (votes for as printed: 81,927,395). Filing ↗ |
| 44 | Section 06, 2025 vote | Form 8-K | 2025-06-13 | 0000950170-25-086130 | Item 5.07 · say-on-pay result. As reported: 93.16% (votes for as printed: 82,619,803). Filing ↗ |
| 45 | Section 06, 2024 vote | Form 8-K | 2024-06-17 | 0000950170-24-073859 | Item 5.07 · say-on-pay result. As reported: 84.68% (votes for as printed: 69,776,291). Filing ↗ |
| 46 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 47 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 48 | Section 09b board cost (computed) | Computed | — | — | Cash 400,000 + equity 1,242,409 + all other 0 = 1,642,409, summed across the director compensation table rows.machine: formula: Σ = 1,642,409 |
| 49 | Doximity, Section 10b CEO total | DEF 14A | 2026-07-15 | 0001516513-26-000032 | CEO total compensation as printed in Doximity's own proxy. As printed: 19,586,169. Filing ↗machine: span 468084–468094 |
| 50 | NovoCure, Section 10b CEO total | DEF 14A | 2026-04-20 | 0001645113-26-000033 | CEO total compensation as printed in NovoCure's own proxy. As printed: 13,198,354. Filing ↗machine: r6 · c48 · span 880842–880852 |
| 51 | Glaukos, Section 10b CEO total | DEF 14A | 2026-04-16 | 0001193125-26-157829 | CEO total compensation as printed in Glaukos's own proxy. As printed: 12,034,087. Filing ↗machine: r6 · c38 · span 1876942–1876952 |
| 52 | Nevro, Section 10b CEO total | DEF 14A | 2024-04-12 | 0000950170-24-044100 | CEO total compensation as printed in Nevro's own proxy. As printed: 11,453,548. Filing ↗machine: r2 · c16 · span 631983–631993 |
| 53 | iRhythm Technologies, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001388658-26-000030 | CEO total compensation as printed in iRhythm Technologies's own proxy. As printed: 11,003,163. Filing ↗machine: r2 · c21 · span 1123498–1123508 |
| 54 | TransMedics Group, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001193125-26-150357 | CEO total compensation as printed in TransMedics Group's own proxy. As printed: 10,915,533. Filing ↗machine: r3 · c39 · span 572169–572179 |
| 55 | Alphatec Holdings (subject), Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191867 | CEO total compensation as printed in Alphatec Holdings's own proxy. As printed: 10,260,507. Filing ↗machine: t26 · r2 · c25 · span 858148–858158 |
| 56 | Maravai Life Sciences Holdings, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001823239-26-000014 | CEO total compensation as printed in Maravai Life Sciences Holdings's own proxy. As printed: 10,129,708. Filing ↗machine: t21 · r3 · c20 · span 502645–502655 |
| 57 | AtriCure, Section 10b CEO total | DEF 14A | 2026-04-06 | 0001323885-26-000010 | CEO total compensation as printed in AtriCure's own proxy. As printed: 9,217,620. Filing ↗machine: span 743364–743373 |
| 58 | LivaNova, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050937 | CEO total compensation as printed in LivaNova's own proxy. As printed: 8,047,217. Filing ↗machine: t117 · r3 · c50 · span 1095329–1095338 |
| 59 | Inspire Medical Systems, Section 10b CEO total | DEF 14A | 2026-03-20 | 0001140361-26-010490 | CEO total compensation as printed in Inspire Medical Systems's own proxy. As printed: 7,711,784. Filing ↗machine: r2 · c25 · span 1164868–1164877 |
| 60 | Artivion, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001999371-26-007510 | CEO total compensation as printed in Artivion's own proxy. As printed: 6,883,108. Filing ↗machine: r3 · c9 · span 741873–741882 |
| 61 | Tandem Diabetes Care, Section 10b CEO total | DEF 14A | 2026-04-07 | 0001438133-26-000034 | CEO total compensation as printed in Tandem Diabetes Care's own proxy. As printed: 6,858,503. Filing ↗machine: r3 · c27 · span 866963–866972 |
| 62 | 10x Genomics, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001628280-26-027201 | CEO total compensation as printed in 10x Genomics's own proxy. As printed: 6,329,244. Filing ↗machine: r3 · c48 · span 583283–583292 |
| 63 | STAAR Surgical, Section 10b CEO total | DEF 14A | 2026-04-10 | 0001500217-26-000023 | CEO total compensation as printed in STAAR Surgical's own proxy. As printed: 4,806,038. Filing ↗machine: r5 · c54 · span 545070–545079 |
| 64 | LeMaitre Vascular, Section 10b CEO total | DEF 14A | 2026-04-14 | 0001193125-26-153877 | CEO total compensation as printed in LeMaitre Vascular's own proxy. As printed: 3,780,990. Filing ↗machine: r3 · c18 · span 564038–564047 |
| 65 | Paragon 28, Section 10b CEO total | DEF 14A | 2026-03-16 | 0001193125-26-108191 | CEO total compensation as printed in Paragon 28's own proxy. As printed: 3,479,531. Filing ↗machine: span 1034121–1034130 |
| 66 | Zynex, Section 10b CEO total | DEF 14A | 2025-03-28 | 0001558370-25-004019 | CEO total compensation as printed in Zynex's own proxy. As printed: 991,810. Filing ↗ |
| 67 | Section 10a, Doximity reciprocity | DEF 14A | — | 0001516513-26-000032 | Doximity's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 68 | Section 10a, Nevro reciprocity | DEF 14A | — | 0000950170-24-044100 | Nevro names Alphatec Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 69 | Section 10a, 10x Genomics reciprocity | DEF 14A | — | 0001628280-26-027201 | 10x Genomics's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 70 | Section 10a, LeMaitre Vascular reciprocity | DEF 14A | — | 0001437749-23-010217 | LeMaitre Vascular's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 71 | Section 10a, STAAR Surgical reciprocity | DEF 14A | — | 0001500217-26-000023 | STAAR Surgical's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 72 | Section 10a, Tandem Diabetes Care reciprocity | DEF 14A | — | 0001438133-26-000034 | Tandem Diabetes Care's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 73 | Section 10a, TransMedics Group reciprocity | DEF 14A | — | 0001193125-26-150357 | TransMedics Group's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 74 | Section 10a, Glaukos reciprocity | DEF 14A | — | 0001193125-26-157829 | Glaukos's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 75 | Section 10a, NovoCure reciprocity | DEF 14A | — | 0001645113-26-000033 | NovoCure's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 76 | Section 10a, Artivion reciprocity | DEF 14A | — | 0001999371-26-007510 | Artivion names Alphatec Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 77 | Section 10a, LivaNova reciprocity | DEF 14A | — | 0001104659-26-050937 | LivaNova's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 78 | Section 10a, iRhythm Technologies reciprocity | DEF 14A | — | 0001388658-26-000030 | iRhythm Technologies names Alphatec Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 79 | Section 10a, Zynex reciprocity | DEF 14A | — | 0001558370-25-004019 | Zynex names Alphatec Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 80 | Section 10a, Paragon 28 reciprocity | DEF 14A | — | 0001193125-26-108191 | Paragon 28's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 81 | Section 10a, AtriCure reciprocity | DEF 14A | — | 0001323885-26-000010 | AtriCure names Alphatec Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Inspire Medical Systems reciprocity | DEF 14A | — | 0001140361-26-010490 | Inspire Medical Systems's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
| 83 | Section 10a, Maravai Life Sciences Holdings reciprocity | DEF 14A | — | 0001823239-26-000014 | Maravai Life Sciences Holdings's most recent proxy was read; its disclosed peer group does not include Alphatec Holdings. Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.